Stablix Entered into a Collaboration and License Agreement with Vertex to Discover and Develop Targeted Protein Stabilization Therapies
Shots:
- Stablix will receive an up front incl. convertible note investment & is also eligible to receive research, development, regulatory and commercial milestones along with royalties on future net sales on any product that resulted from the collaboration
- Vertex to get an exclusive license to certain molecules & will lead the development and commercialization along with research costs associated with the collaboration
- The collaboration uses Stablix’s proprietary targeted protein stabilization platform to discover novel heterobifunctional small molecule drug candidates (RESTORACs) against specified targets involved in multiple diseases
Ref: Globenewswire | Image: Vertex
Rlated News:- Vertex Receives the US FDA’s IND Clearance of VX-264 for the Treatment of Type 1 Diabetes
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
